Complaint challenges the American Society of Anesthesiologists for promoting biased, analytically misguided studies in its journal, on its website, and through CME activity PARSIPPANY, N.J., April 14, ...
sNDA submission based on positive Phase 3 data supporting expansion of the EXPAREL label to include use in children aged six and over PARSIPPANY, N.J., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Pacira ...
EXPAREL (bupivacaine liposome injectable suspension) is currently indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The product combines bupivacaine with ...
SAN DIEGO, and PARSIPPANY, N.J., Feb. 15, 2011 /PRNewswire via COMTEX/ -- Pacira Pharmaceuticals, Inc., (Nasdaq: PCRX), an emerging specialty pharmaceutical company, today announced that additional ...
NEW YORK--(BUSINESS WIRE)--Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced results from EXCLAIM, its Phase 4 prospective, observational study to assess the use of EXPAREL® (bupivacaine ...
PARSIPPANY, N.J.-- Pacira Pharmaceuticals, Inc.(NASDAQ: PCRX) today announced the receipt of a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) following a review of its ...
A few years ago when Dr. Thomas Horn performed a tummy tuck on patients, they would be admitted to the hospital for intravenous narcotic pain management during the procedure and sent home with a ...
(Reuters) - Pacira Pharmaceuticals Inc said a late-stage study showed the painkiller, Exparel, significantly reduced pain for a wider range of patients after surgery, sending its shares up 5 percent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results